Bioworld by clarivate examines impact of emerging medicines on obesity

Three-part, in-depth analysis of biopharma investments in obesity medications highlights potential impact on patient population historically faced with limited options london , oct. 24, 2023 /prnewswire/ -- bioworld™ published by clarivate plc (nyse:clvt), a global leader in connecting people and organizations to intelligence they can trust to transform their world, examines the impact of emerging obesity medicines in a new three-part series, the rise of obesity. the special coverage offers in-depth analysis of how the anticipated multibillion-dollar market potential for obesity medications in the coming years will impact biopharma, insurance companies and a patient population in need of safer options.
CLVT Ratings Summary
CLVT Quant Ranking